116 related articles for article (PubMed ID: 33355372)
41. MicroRNA‑149‑3p inhibits cell proliferation by targeting AKT2 in oral squamous cell carcinoma.
Shen Q; Zhu H; Lei Q; Chen L; Yang D; Sui W
Mol Med Rep; 2021 Mar; 23(3):. PubMed ID: 33398370
[TBL] [Abstract][Full Text] [Related]
42. Knocking-down of CREPT prohibits the progression of oral squamous cell carcinoma and suppresses cyclin D1 and c-Myc expression.
Ma J; Ren Y; Zhang L; Kong X; Wang T; Shi Y; Bu R
PLoS One; 2017; 12(4):e0174309. PubMed ID: 28369091
[TBL] [Abstract][Full Text] [Related]
43. [Effect of the conjugate composed of a human monoclonal antibody and pingyangmycin on mammary cancer].
Wang WG; Wang SH; Xue YC; Zhen YS
Yao Xue Xue Bao; 1995; 30(8):583-7. PubMed ID: 8571778
[TBL] [Abstract][Full Text] [Related]
44. Novel nalidixic acid derivatives targeting topoisomerase II enzyme; Design, synthesis, anticancer activity and effect on cell cycle profile.
Khalil OM; Gedawy EM; El-Malah AA; Adly ME
Bioorg Chem; 2019 Mar; 83():262-276. PubMed ID: 30391699
[TBL] [Abstract][Full Text] [Related]
45. Synergistic effect of nanosecond pulsed electric field combined with low-dose of pingyangmycin on salivary adenoid cystic carcinoma.
Qi W; Guo J; Wu S; Su B; Zhang L; Pan J; Zhang J
Oncol Rep; 2014 May; 31(5):2220-8. PubMed ID: 24604118
[TBL] [Abstract][Full Text] [Related]
46. Antitumor effects of monoclonal antibody Fab' fragment-containing immunoconjugates.
Liu X; Zhen Y
Chin Med Sci J; 2002 Mar; 17(1):1-6. PubMed ID: 12894876
[TBL] [Abstract][Full Text] [Related]
47. [Preparation of lymphatic targeting dosage form: pingyangmycin absorbed on activated carbon nanoparticles].
Sun ML; Wen YM; Wang CM; Li LJ; Wang XY
Hua Xi Kou Qiang Yi Xue Za Zhi; 2004 Jun; 22(3):183-5. PubMed ID: 15293458
[TBL] [Abstract][Full Text] [Related]
48. Chitosan-based liposomal thermogels for the controlled delivery of pingyangmycin: design, optimization and in vitro and in vivo studies.
Zhang L; Chen F; Zheng J; Wang H; Qin X; Pan W
Drug Deliv; 2018 Nov; 25(1):690-702. PubMed ID: 29484910
[TBL] [Abstract][Full Text] [Related]
49. [Effects of Pingyangmycin albumin microspheres on sclerostenosis of the rabbit central auricular arteries].
Gao QH; Zheng GJ; Wang XY; Zhou L; Dong JZ; Wang CM; Wen YM
Shanghai Kou Qiang Yi Xue; 2005 Feb; 14(1):42-7. PubMed ID: 15747013
[TBL] [Abstract][Full Text] [Related]
50. miR‑135b‑5p enhances the sensitivity of HER‑2 positive breast cancer to trastuzumab via binding to cyclin D2.
Li Z; Qin Y; Chen P; Luo Q; Shi H; Jiang X
Int J Mol Med; 2020 Oct; 46(4):1514-1524. PubMed ID: 32700749
[TBL] [Abstract][Full Text] [Related]
51. [Lymphatic targeting study of pingyangmycin-activated carbon nanoparticles treating oral cancer lymph node metastasis].
Sun ML; Xie WH; Wang CM; Wen YM
Hua Xi Kou Qiang Yi Xue Za Zhi; 2011 Jun; 29(3):253-6, 263. PubMed ID: 21776848
[TBL] [Abstract][Full Text] [Related]
52. Prognostic and predictive value of the combination of TOP2A and HER2 in node-negative tumors 2 cm or smaller (T1N0) breast cancer.
Zhong W; Yang Y; Zhang A; Lin W; Liang G; Ling Y; Zhong J; Yong J; Liu Z; Tian Z; Lin Q; Luo Q; Li Y; Gong C
Breast Cancer; 2020 Nov; 27(6):1147-1157. PubMed ID: 32780321
[TBL] [Abstract][Full Text] [Related]
53. SPOP is essential for DNA-protein cross-link repair in prostate cancer cells: SPOP-dependent removal of topoisomerase 2A from the topoisomerase 2A-DNA cleavage complex.
Watanabe R; Maekawa M; Hieda M; Taguchi T; Miura N; Kikugawa T; Saika T; Higashiyama S
Mol Biol Cell; 2020 Mar; 31(6):478-490. PubMed ID: 31967940
[TBL] [Abstract][Full Text] [Related]
54. A novel all-trans retinoic acid derivative 4-amino‑2‑trifluoromethyl-phenyl retinate inhibits the proliferation of human hepatocellular carcinoma HepG2 cells by inducing G0/G1 cell cycle arrest and apoptosis via upregulation of p53 and ASPP1 and downregulation of iASPP.
Liu H; Chen F; Zhang L; Zhou Q; Gui S; Wang Y
Oncol Rep; 2016 Jul; 36(1):333-41. PubMed ID: 27177208
[TBL] [Abstract][Full Text] [Related]
55. Percutaneous Treatment of Large Venous Malformations in the Oral and Maxillofacial Regions Using Electrochemical Therapy Combined With Pingyangmycin.
Xue L; Cao RY; Xu DP; Sun NN; Tan HS; Wang XK
J Oral Maxillofac Surg; 2015 Jul; 73(7):1384-91. PubMed ID: 25913514
[TBL] [Abstract][Full Text] [Related]
56. Evaluation of TOP2A as a Predictive Marker for Endometrial Cancer With Taxane-Containing Adjuvant Chemotherapy.
Ito F; Furukawa N; Nakai T
Int J Gynecol Cancer; 2016 Feb; 26(2):325-30. PubMed ID: 26588239
[TBL] [Abstract][Full Text] [Related]
57. The ZATT-TOP2A-PICH Axis Drives Extensive Replication Fork Reversal to Promote Genome Stability.
Tian T; Bu M; Chen X; Ding L; Yang Y; Han J; Feng XH; Xu P; Liu T; Ying S; Lei Y; Li Q; Huang J
Mol Cell; 2021 Jan; 81(1):198-211.e6. PubMed ID: 33296677
[TBL] [Abstract][Full Text] [Related]
58. [Expression of X-linked inhibitor of apoptosis protein in Tca8113 cell and its relationship to chemoresistance].
Wang JF; Zhang ZM; Wang CK; Nie DB; Gao WX
Hua Xi Kou Qiang Yi Xue Za Zhi; 2010 Feb; 28(1):92-4. PubMed ID: 20337086
[TBL] [Abstract][Full Text] [Related]
59. [Relevance between TOP2A, EGFR gene expression and efficacy of docetaxel plus epirubicin as neoadjuvant chemotherapy in triple negative breast cancer patients].
Liu L; Li XR; Hu YH; Zhang J
Zhonghua Yi Xue Za Zhi; 2016 Mar; 96(12):940-3. PubMed ID: 27045718
[TBL] [Abstract][Full Text] [Related]
60. [Anticancer spectrum of pingyangmycin in vitro].
Li XT
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1990 Jun; 12(3):182-6. PubMed ID: 1706647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
